There have been aspirations for closer collaboration between European Union (EU) Member States (MS) on Health Technology Assessment (HTA) for at least two decades.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.